Intellia Therapeutics, Inc. (NTLA) Downgraded to Underperform by Wolfe Research

Market Context

Intellia Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $11.86 with a market capitalization of $1.0B.

Analyst downgrades can weigh on a stock in the short term as institutional investors who follow Wolfe Research's research adjust their positions. However, downgrades also sometimes create buying opportunities if the market overreacts to the rating change. The reasoning behind the downgrade matters more than the rating itself.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Intellia Therapeutics, Inc.

Among the 10 most recent ratings: 5 Buy, 4 Hold, 1 Sell.

Date	Firm	Rating	Price Target
Jul 16, 2026	Wolfe Research	Underperform	N/A
Jul 10, 2026	Wedbush	Neutral	N/A
Jun 16, 2026	Canaccord Genuity	Buy	N/A
Jun 15, 2026	Citizens	Market Outperform	N/A
Jun 15, 2026	Wedbush	Neutral	N/A

Related Tools: Analyst Ratings Dashboard | View NTLA Stock Page